Common PSMF Inspection Findings

Introduction

The Pharmacovigilance System Master File is one of the most frequently reviewed documents during a pharmacovigilance inspection.

Inspectors commonly request the PSMF before the inspection begins and use it to build their initial understanding of the pharmacovigilance system.

For this reason, weaknesses within the PSMF often influence the entire inspection.

A well-maintained PSMF can help inspectors quickly understand:

• Organisational structure
• Governance arrangements
• Vendor oversight
• Product scope
• Compliance controls

A poor PSMF may create concerns before operational processes are even reviewed.

Understanding common findings therefore provides valuable insight into how inspectors assess pharmacovigilance systems.

What Inspectors Are Actually Assessing

Many organisations assume inspectors are reviewing the PSMF simply to verify compliance with regulatory requirements.

In reality, inspectors are usually trying to answer three questions:

Question 1

Does the organisation understand its pharmacovigilance system?

Question 2

Does the organisation control its pharmacovigilance system?

Question 3

Can the organisation demonstrate that control?

The PSMF becomes one of the most important tools inspectors use to answer those questions.

Why PSMF Findings Matter

PSMF findings rarely exist in isolation.

An outdated product inventory may suggest:

• Poor governance
• Weak change control
• Inadequate oversight

An incomplete vendor inventory may suggest:

• Outsourcing risks
• Compliance monitoring gaps
• Unclear responsibilities

Consequently, PSMF findings often trigger broader inspection scrutiny.

Inspectors frequently view the document as an indicator of overall system maturity.

Finding Category 1: Outdated Information

The most common PSMF finding is simple.

The document no longer reflects reality.

Examples include:

• Former QPPVs still listed
• Obsolete organisational charts
• Retired systems
• Former vendors
• Outdated product inventories

These findings often arise because organisations treat the PSMF as a periodic document review exercise rather than a continuously maintained governance tool.

Root Cause

Usually:

• Weak ownership
• Weak change control
• Lack of governance integration

Preventive Approach

Integrate PSMF updates into:

• Change control
• Vendor onboarding
• Product lifecycle management
• Organisational restructuring

Finding Category 2: Missing Vendors

Outsourcing has become a central component of modern pharmacovigilance systems.

Inspectors therefore expect visibility regarding:

• Who performs activities
• Which activities are outsourced
• How oversight is maintained

Common findings include:

• Missing vendors
• Incomplete inventories
• Missing oversight descriptions
• Inconsistent vendor information

Why Inspectors Care

Because outsourcing does not transfer accountability.

The MAH remains responsible.

Typical Inspection Question

Show me all vendors performing pharmacovigilance activities.

If the organisation cannot answer consistently, concerns arise quickly.

Finding Category 3: Incomplete Product Inventories

The product inventory defines the scope of the pharmacovigilance system.

Common deficiencies include:

• Missing products
• Incorrect marketing status
• Delayed updates after acquisitions
• Withdrawn products remaining active

Inspectors frequently compare product inventories against:

• Regulatory records
• Marketing authorisations
• Organisational product lists

Discrepancies may indicate wider governance weaknesses.

Finding Category 4: Organisational Structures That Do Not Match Reality

Many PSMFs contain organisational charts.

Inspectors often verify these through interviews.

Examples of findings include:

• Incorrect reporting lines
• Missing functions
• Unclear responsibilities
• Outdated affiliate structures

These deficiencies may make it difficult for inspectors to determine accountability.

Finding Category 5: Weak QPPV Documentation

Because the QPPV occupies a central role within the pharmacovigilance system, inspectors frequently review QPPV information early.

Common findings include:

• Incorrect contact information
• Missing deputy arrangements
• Unclear responsibilities
• Inconsistencies between documents

These findings often attract attention because they affect accountability.

Finding Category 6: Annexes That Are Not Maintained

Many organisations focus heavily on the main body of the PSMF.

Annexes receive less attention.

This creates risk because annexes often contain the most dynamic information.

Examples include:

• Product inventories
• Vendor inventories
• Audit programmes
• Inspection histories

Inspectors frequently discover that annexes have not been updated for extended periods.

For additional information see:

[[psmf-annexes-guide]]

Finding Category 7: Governance Descriptions That Do Not Reflect Practice

This is one of the most serious categories of findings.

The PSMF may describe:

• Governance committees
• Escalation processes
• Oversight activities

However, inspection evidence may demonstrate that those activities do not actually occur.

Examples include:

• Committees that rarely meet
• Missing minutes
• Escalations that never occur
• Metrics that are not reviewed

Inspectors often regard these findings as more significant than administrative errors.

Finding Category 8: Weak Vendor Oversight Descriptions

Inspectors increasingly focus on outsourced pharmacovigilance activities.

Common deficiencies include:

• Lack of oversight descriptions
• Missing governance activities
• Unclear responsibilities
• Incomplete documentation

A vendor may perform activities effectively.

If oversight cannot be demonstrated, findings may still occur.

Finding Category 9: Inadequate Traceability

Traceability is often overlooked.

Inspectors should be able to move easily between:

• PSMF statements
• Procedures
• Contracts
• Inventories
• Operational evidence

Poor traceability creates inefficiency and may reduce confidence in the document.

Finding Category 10: PSMF Treated as an Inspection Document

This is arguably the most important finding category.

The organisation updates the PSMF:

• Before inspections
• Before audits
• Before authority requests

But not during normal operations.

This often produces a predictable cycle:

1. Document quality deteriorates.
2. Inspection approaches.
3. Intensive remediation occurs.
4. Quality improves temporarily.
5. Deterioration resumes.

Mature organisations avoid this cycle entirely.

The Real Root Causes

Although findings appear diverse, most originate from a small number of root causes.

Governance Failure

Nobody actively governs the PSMF.

Ownership Failure

Responsibilities are unclear.

Change Control Failure

System changes do not trigger PSMF updates.

Oversight Failure

Review activities are ineffective.

Resource Failure

Insufficient capacity exists to maintain the document.

Understanding these root causes is usually more valuable than understanding individual findings.

CAPAs Following PSMF Findings

Effective CAPAs focus on system improvement rather than document correction.

Weak CAPA:

Update vendor inventory.

Strong CAPA:

Integrate vendor onboarding and termination activities into PSMF governance procedures.

The difference is important.

One fixes a symptom.

The other addresses a root cause.

What Great Organisations Do Differently

High-performing organisations tend to share several characteristics.

Defined Ownership

Every major annex has an owner.

Change Control Integration

Updates are triggered automatically by relevant business changes.

Regular Governance Reviews

PSMF health is reviewed routinely.

Inspection Readiness Culture

The PSMF remains inspection-ready continuously.

QPPV Engagement

The QPPV understands and actively uses the document.

Inspector Psychology

One of the most useful concepts for organisations is understanding inspector psychology.

Inspectors are not trying to find typographical errors.

They are trying to determine whether the pharmacovigilance system is:

• Understood
• Controlled
• Governed
• Sustainable

The PSMF provides one of the clearest windows into those questions.

Key Takeaways

• PSMF findings frequently reflect broader governance weaknesses.
• Outdated information remains the most common deficiency.
• Vendor inventories and product inventories are frequent inspection focus areas.
• Governance descriptions must accurately reflect operational reality.
• Strong CAPAs address root causes rather than document errors.
• Mature organisations maintain inspection readiness continuously.
• Inspectors often view PSMF quality as an indicator of pharmacovigilance system maturity.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
2. EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
3. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
4. Regulation (EC) No 726/2004.
5. Directive 2001/83/EC.
6. Commission Implementing Regulation (EU) No 520/2012.
7. EMA Questions and Answers on Pharmacovigilance System Master Files.